基本信息
浏览量:3
职业迁徙
个人简介
My own personal interests have been in the area of diagnosis of DVT and pulmonary embolism and this has led to the development of diagnostic algorithms and strategies, which are widely described as the Wells' Models or Wells' Scores. i am extremely proud that these tools are used world-wide but as with all research, I hope that these tools will one day be improved upon. I remain actively interested in performing research in the area of thrombophilia, but largely through partnerships with other investigators such as Dr. France Gagnon, Canada research Chair at the University of Toronto. I have also had an interest in improving the management of patients on Vitamin K antagonist and continue to perform studies looking at the influence of patients genotypes on dosing, both for initiation and maintenance of Vitamin K antagonist therapy. I am currently performing a large multi-centre study, funded by Heart & Stroke Foundation of Ontario. trying to establish a prediction tool for bleeding risk. our hope is to create a tool that will predict bleeding beyond 3 to 6 months of anticoagulant therapy, as this is a critical time when decisions must be made as to whether anticoagulants should be continued. The missing part of the equation (we have done extensive research led by Dr. Rodger in our group here in Ottawa on risk of recurrence), is the risk of major bleeding. The more recent focus of my research and collaboration, with Dr. Marc Carrier who leads the Cancer Thrombosis Program in the Dept. of Medicine, is thrombotic disorders associated with cancer. Patients with cancer have a very high risk of recurrent venous thrombosis despite standard therapy with low molecular weight heparin and we hope to establish which patients are likely to fail therapy and the ideal therapeutic modalities for patients who recur. Furthermore, we are very excited by the possibility of using published clinical prediction rules for risk of developing thrombosis in patients who recently had cancer diagnoses and have just started therapy. To date, prophylaxis for venous thrombosis is not standard therapy in cancer patients and it is our belief that with appropriate research, we will be able to target the appropriate patients in whom the risk-benefit profile of using anticoagulant therapy is such that therapy would be indicated. For our research in this area, we hope to be looking at the new oral anticoagulant medicines, such as Dabigatran, Rivaroxaban or Apixaban. The new oral anticoagulants represent great research opportunities for our group and we paln to perform many studies with these new medicines. one of the first studies that we hope to conduct is in the area of adherence to therapy, as there are some concerns that with the lack of monitoring, adherence to anticoagulant therapy may be less than ideal. This is just a snapshot of the research that I and my colleagues in Ottawa perform. I encourage you to look through this website for work that our group has published and for future projects.
研究兴趣
论文共 630 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Research and practice in thrombosis and haemostasisno. 2 (2024): 102360-102360
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASISno. 1 (2024): 102274-102274
Dieuwke Luijten,Delphine Douillet,Kim Luijken,Cecile Tromeur,Andrea Penaloza, Olivier Hugli,Drahomir Aujesky,Stefano Barco,Joseph R Bledsoe, Kyle E Chang, Francis Couturaud,Paul L den Exter,
European heart journal (2024)
Research and Practice in Thrombosis and Haemostasisno. 3 (2024): 102403-102403
Research and Practice in Thrombosis and Haemostasispp.102360, (2024)
Marie-Eve Mathieu,Lisa Duffett,Lucia Caiano, Dimitri Scarvelis,Catherine Code,Philip Wells,Gregoire Le Gal
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASISno. 1 (2024): 102263-102263
AMERICAN JOURNAL OF HEMATOLOGYno. 4 (2024): 577-585
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn